Celecoxib in Preventing the Damaging Effects of Sunburn in Healthy

Status Completed

Clinical Trial Summary

This randomized clinical trial studies if celecoxib will prevent the damaging effects of sunburn in healthy volunteers. Exposure to ultraviolet light can induce erythema, sunburn or skin redness caused by inflammation. Celecoxib may reduce skin damage by blocking enzymes associated with sunburn in healthy volunteers. Studying samples of skin in the laboratory from patients receiving ultraviolet-radiation before and after celecoxib treatment may help doctors learn more about the effects celecoxib has on cells.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. Quantify changes in the erythema response in human subjects exposed to minimally erythemic doses of solar-simulated ultraviolet light before and after celecoxib treatment.

II. Determine the effect of celecoxib on various biomarkers following ultraviolet (UV)-irradiation. The modulation of the following biomarkers, before and after treatment with celecoxib are being examined: apoptosis and proliferation indices, prostaglandin E2 (PGE2), cyclooxygenase-1 (COX-1), and cyclooxygenase- 2 (COX-2) levels.

OUTLINE:

Patients undergo UV-irradiation to the right buttock at baseline. Chromameter readings are obtained at 24 hours post UV-irradiation and patients undergo skin biopsy at 24 and 96 hours following UV-irradiation.

Patients are then randomized to 1 of 5 treatment groups.

GROUP I: Patients receive placebo orally (PO) twice daily (BID) for 14 days.

GROUP II: Patients receive low-dose celecoxib PO BID for 14 days.

GROUP III: Patients receive higher dose celecoxib PO BID for 14 days.

GROUP IV: Patients receive same dose of celecoxib PO as Group III once daily (QD) for 14 days.

GROUP V: Patients receive high-dose celecoxib PO QD for 14 days.

After 10 days post-treatment, patients undergo UV-irradiation to the left buttock. Chromameter readings are obtained at 24 hours post UV-irradiation and patients undergo skin biopsy at 24 and 96 hours following UV-irradiation.

After completion of study treatment, patients are followed up at day 25. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

No Evidence of Disease

Clinical Trial Details

NCT number	NCT02099136
Study type	Interventional
Source	National Cancer Institute (NCI)
Contact
Status	Completed
Phase	Phase 2
Start date	September 1999
Completion date	December 2004

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT01230346` - Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer	N/A
Recruiting	`NCT03156309` - Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission	Phase 1
Active, not recruiting	`NCT02780401` - Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission	Phase 1
Completed	`NCT03725449` - Internet-based Intervention for Skin Self-Examination in Participants With Increased Risk for Melanoma	N/A
Completed	`NCT01497431` - Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants	Phase 1
Withdrawn	`NCT03120390` - Physical Activity in Reducing Metabolic Dysregulation (MetD) in Obese Latina Breast Cancer Survivors	N/A
Completed	`NCT02090933` - Celecoxib in Decreasing the Damaging Effects of Sunburn in Healthy Volunteers	Phase 2
Terminated	`NCT02735512` - MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer
Completed	`NCT01149096` - Collection of Bone Marrow From Donors Treated With or Without Filgrastim	Phase 3
Completed	`NCT02961790` - Oxybutynin Chloride in Managing Hot Flashes	Phase 3
Completed	`NCT02288416` - Video-Based Intervention in Reducing Anxiety in Patients Undergoing Lung Cancer Screening	N/A
Completed	`NCT01698294` - Biomarkers in Post-Menopausal Women Receiving Flaxseed	N/A
Completed	`NCT00896974` - Study of 9cUAB30 in Healthy Participants	Phase 1
Terminated	`NCT03284346` - Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Celecoxib in Preventing the Damaging Effects of Sunburn in Healthy Volunteers

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms